| Window | Theses | Resolved | Wins | Win rate | Avg return | Median return |
|---|---|---|---|---|---|---|
| 1d | 1 | 1 | 0 | 0% | -0.2% | -0.2% |
| 3d | 1 | 1 | 0 | 0% | -0.2% | -0.2% |
| 1w | 1 | 1 | 1 | 100% | +7.0% | +7.0% |
| 1m | 0 | 0 | 0 | — | — | — |
| 3m | 0 | 0 | 0 | — | — | — |
| 6m | 0 | 0 | 0 | — | — | — |
| 1y | 0 | 0 | 0 | — | — | — |
Past performance does not predict future results. Informational only, not investment advice.
CVRx is trading at $2.80 with a pending strategic review demanded by a major shareholder. An announcement of hiring an investment bank to evaluate alternatives could immediately trigger a 2x move, with potential upside expanding as acquisition speculation accelerates among MedTech buyers.
Multiple senior executives (CEO, CFO, CLO) and a director simultaneously purchased significant amounts of shares using personal capital on August 12, 2026. Cluster buying by top management is historically a bullish signal indicating confidence in the company's future performance and current valuation.
End of results.